Business Wire26d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
In this aggressive and rare form of cutaneous T-cell lymphoma, patients in advanced disease often experience very poor quality of life and are in strong need of new, targeted treatment options ...
Hosted on MSN3mon
'I've got to stay strong, despite cancer anxiety'
Mr O'Connor was diagnosed with a rare type of lymphoma called Sezary syndrome in 2022. He is in urgent need of a stem cell donor, but his Jamaican heritage is complicating the process.
Yahoo Finance26d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab.